Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer

Published:2023-06-23 Issue:4 Volume:18 Page:625-636
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Zheng Nan,Zhang Yimin,Zeng Yue,Ma Qiang,Zhang Ruiguang,Zhao Qian,Lu Conghua,Tian Jie,Wang ZhiGuo,Tang Huan,Luo Nuo,Xiao Hualiang,He Yong,Wu Fang,Li Li

Funder

National Natural Science Foundation of China

Natural Science Foundation of Chongqing Municipality

Clinical Medical Research Talent Training Program of Army Medical University

Clinical medical technology innovation ability training program

Guangdong Association of Clinical Trials (GACT) /Chinese Thoracic Oncology Group

The Science Foundation for Outstanding Young People of the Army Medical University

The Science Fundation of Daping Hospital, Army Medical University

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s11523-023-00981-7.pdf

Reference28 articles.

1. Arriagada R, Auperin A, Burdett S, Higgins JP, Johnson DH, Le Chevalier T, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet. 2010;375(9722):1267–77. https://doi.org/10.1016/s0140-6736(10)60059-1.

2. NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383(9928):1561–71. https://doi.org/10.1016/s0140-6736(13)62159-5.

3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–703. https://doi.org/10.1056/NEJMoa1006448.

4. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, Iyer S. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl j Med. 2014;371:2167–77.

5. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004–12. https://doi.org/10.1016/s1470-2045(11)70232-7.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterizing the immune tumor microenvironment in ALK fusion-positive lung cancer: state-of-the-art and therapeutical implications;Expert Review of Clinical Immunology;2024-06-26

2. Understanding the dynamics of TKI-induced changes in the tumor immune microenvironment for improved therapeutic effect;Journal for ImmunoTherapy of Cancer;2024-06

3. Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions;Biomedicines;2024-01-27